MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 15; no. 3; p. 297
• Main Authors: Moro, Massimo, Fortunato, Orazio, Bertolini, Giulia, Mensah, Mavis, Borzi, Cristina, Centonze, Giovanni, Andriani, Francesca, Di Paolo, Daniela, Perri, Patrizia, Ponzoni, Mirco, Pastorino, Ugo, Sozzi, Gabriella, Boeri, Mattia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28-02-2022; MDPI
• Subjects: Apoptosis; cancer stem cell; Experiments; Kinases; Lung cancer; Medical screening; Metastasis; microRNA; MicroRNAs; Phosphorylation; Proteins; Stem cells; Tumors; lung cancer; cancer stem cell; microRNA
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph15030297

Despite improvements in therapies and screening strategies, lung cancer prognosis still remains dismal, especially for metastatic tumors. Cancer stem cells (CSCs) are endowed with properties such as chemoresistance, dissemination, and stem-like features, that make them one of the main causes of the poor survival rate of lung cancer patients. MicroRNAs (miRNAs), small molecules regulating gene expression, have a role in lung cancer development and progression. In particular, miR-486-5p is an onco-suppressor miRNA found to be down-modulated in the tumor tissue of lung cancer patients. In this study, we investigate the role of this miRNA in CD133+ lung CSCs and evaluate the therapeutic efficacy of coated cationic lipid-nanoparticles entrapping the miR-486-5p miRNA mimic (CCL-486) using lung cancer patient-derived xenograft (PDX) models. In vitro, miR-486-5p overexpression impaired the PI3K/Akt pathway and decreased lung cancer cell viability. Moreover, miR-486-5p overexpression induced apoptosis also in CD133+ CSCs, thus affecting the in vivo tumor-initiating properties of these cells. Finally, we demonstrated that in vivo CCL-486 treatment decreased CD133+ percentage and inhibited tumor growth in PDX models. In conclusion, we provided insights on the efficacy of a novel miRNA-based compound to hit CD133+ lung CSCs, setting the basis for new combined therapeutic strategies.